New diabetes drug ecnoglutide shows promise in Late-Stage trial
NCT ID NCT05680155
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 36 times
Summary
This study tested a new drug called ecnoglutide (XW003) in 211 adults with type 2 diabetes that was not well controlled by diet and exercise alone. Participants received either the drug or a placebo as a weekly injection. The main goal was to see if ecnoglutide could safely lower blood sugar levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ecnoglutide (XW003), a drug given as a shot under the skin
What this could lead to
If it works, this could offer a new once-weekly injection to help people with type 2 diabetes lower their blood sugar and possibly lose weight.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects like nausea or hypoglycemia are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.